M. Ravic

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp et al. · Blood · 2015 · 330 citations · Full text

Life Sciences, Immunology, Oncology +16

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

D. Pantoflickova, Gian Dorta, M. Ravic et al. · Alimentary Pharmacology & Therapeutics · 2003 · 139 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent

Mark J. McKeage, Peter C.C. Fong, Mark Jeffery et al. · Clinical Cancer Research · 2006 · 93 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer

Éric Raymond, W.W. ten Bokkel Huinink, Jos H. Beijnen et al. · Journal of Clinical Oncology · 2002 · 64 citations

Pharmacy, Oncology, Pharmacology +16

Phase II study of E7070 in patients with metastatic melanoma

J F Smyth, S. Aamdal, Ahmad Awada et al. · Annals of Oncology · 2004 · 60 citations · Full text

Medicine, Clinical Sciences, Oncology +13